drugset / Trial / NCT00027638
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Treatment
Summary
RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine tumors.
Timeline
- Start
- 2001-03
- Primary completion
- 2003-12
- Completion
- 2003-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thalidomide | Other / unclassified | — | Oral |